Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
Felicitas Thol , Razif Gabdoulline , Alessandro Liebich , Piroska Klement
Blood 132 ( 16) 1703 -1713
104
2018
Reduced Intensity Conditioning with Fludarabine, BCNU and Melphalan (FBM) for Allogeneic Hematopoietic Cell Transplantation in Elderly AML Patients: Factors Predicting Outcome
Verena Wais , Stephan Bohl , Lukas Kündgen , Stephanie von Harsdorf
Blood 126 ( 23) 5523 -5523
2015
The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance])
Richard M. Stone , Sumithra Mandrekar , Ben L Sanford , Susan Geyer
Blood 126 ( 23) 6 -6
128
2015
An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)
Andrea Kuendgen , Heinz Tuechler , Meritxell Nomdedeu , Guillermo Garcia-Manero
Blood 126 ( 23) 609 -609
7
2015
Dissecting Genetic and Phenotypic Heterogeneity to Map Molecular Phylogenies and Deliver Personalized Outcome and Treatment Predictions in AML
Elli Papaemmanuil , Moritz Gerstung , Lars Bullinger , Verena I. Gaidzik
Blood 126 ( 23) 803 -803
5
2015
A Phase-Ib/II Study of Ruxolitinib Plus Pomalidomide in Myelofibrosis
Frank Stegelmann , Markus Bangerter , Florian H Heidel , Martin Griesshammer
Blood 126 ( 23) 826 -826
8
2015
Personally Tailored Risk Prediction of AML Based on Comprehensive Genomic and Clinical Data
Moritz Gerstung , Elli Papaemmanuil , Inigo Martincorena , Lars Bullinger
Blood 126 ( 23) 85 -85
2
2015
Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)
Andrea Kuendgen , Heinz Tuechler , Meritxell Nomdedeu , Detlef Haase
Blood 128 ( 22) 112 -112
2
2016
Minimal Residual Disease Monitoring in Acute Myeloid Leukemia (AML) with Translocation t(8;21)(q22;q22): Results of the AML Study Group (AMLSG)
Mridul Agrawal , Andrea Corbacioglu , Peter Paschka , Daniela Weber
Blood 128 ( 22) 1207 -1207
16
2016
CDK4/6 Inhibitor Palbociclib for Treatment of KMT2A-Rearranged Acute Myeloid Leukemia: Interim Analysis of the AMLSG 23-14 Trial
Stefan Fröhling , Mridul Agrawal , Nikolaus Jahn , Lars R. Fransecky
Blood 128 ( 22) 1608 -1608
7
2016
Ruxolitinib Plus Pomalidomide in Myelofibrosis: Updated Results from the Mpnsg-0212 Trial (NCT01644110)
Frank Stegelmann , Holger Hebart , Markus Bangerter , Denise Wolleschak
Blood 128 ( 22) 1939 -1939
4
2016
Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry
Uwe Platzbecker , Eva Lengfelder , Katharina S Goetze , Christoph Röllig
Blood 128 ( 22) 2815 -2815
2016
Additional Genetic High-Risk Features Such As 11q Deletion, 17p Deletion, and V3-21 Usage Characterize Discordance of ZAP-70 and VH Mutation Status in Chronic Lymphocytic Leukemia
Alexander Kröber , Johannes Bloehdorn , Sebastian Hafner , Andreas Bühler
Journal of Clinical Oncology 24 ( 6) 969 -975
181
2006
Updated definition of cure in adult patients with non-APL acute myeloid leukemia
Gevorg Tamamyan , Konstanze Döhner , Gautham Borthakur , Peter Paschka
Clinical Lymphoma, Myeloma & Leukemia 15
1
2015
Molecular Characterization of Relapsed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML)
Mridul Agrawal , Andrea Corbacioglu , Nikolaus Jahn , Lars Bullinger
Blood 126 ( 23) 2586 -2586
1
2015
Pharmacodynamic Monitoring of the Efficacy of a Targeted Therapy with Midostaurin By Plasma Inhibitor Activity (PIA) Analysis in FLT3 -ITD Positive AML Patients within the AMLSG 16-10 Trial: A Study of the AML Study Group (AMLSG)
Frauke Theis , Peter Paschka , Daniela Weber , Verena I. Gaidzik
Blood 126 ( 23) 2585 -2585
2
2015
A Phase 1b Study of Panobinostat in Combination with Idarubicin and Ara-C in Patients with High-Risk Acute Myeloid Leukemia
Jorge Sierra , Bruno C. Medeiros , Enrique M. Ocio , Christoph Röllig
Blood 126 ( 23) 2553 -2553
1
2015
Clonal Evolution in NPM1 Mutated Acute Myeloid Leukemia (AML)
Silke Kapp-Schwoerer , Sibylle Cocciardi , Jan Kroenke , Anna Dolnik
Blood 126 ( 23) 1381 -1381
1
2015
Phase 2 Study of Monotherapy Galunisertib (LY2157299 Monohydrate) in Very Low-, Low-, and Intermediate-Risk Patients with Myelodysplastic Syndromes
David Valcarcel , Amit Verma , Uwe Platzbecker , Valeria Santini
Blood 126 ( 23) 1669 -1669
13
2015
Monitoring of Minimal Residual Disease (MRD) of DNMT3A Mutations (DNMT3Amut) in Acute Myeloid Leukemia (AML): A Study of the AML Study Group (AMLSG)
Verena I. Gaidzik , Daniela Weber , Peter Paschka , Anna Kaumanns
Blood 126 ( 23) 226 -226
3
2015